HCV-targeted antivirals: current status and future challenges.

Area of Science:

• Virology
• Hepatology
• Drug Discovery

Background:

• Hepatitis C virus (HCV) affects over 170 million globally, causing non-A, non-B hepatitis.
• Current standard treatments (ribavirin + interferon-α) have significant side effects, resistance issues, and genotype-specific efficacy limitations.

Purpose of the Study:

• To review recent advances in the rational drug design of small-molecule inhibitors targeting HCV.
• To discuss the development of inhibitors for viral enzymes like NS3/4A, NS5B, and NS5A, including those active against resistant strains.

Main Methods:

• Review of recent scientific literature on HCV drug discovery.
• Analysis of clinical trial data for approved HCV antivirals (boceprevir, telaprevir).
• Discussion of ongoing research into novel small-molecule inhibitors targeting specific HCV proteins.

Main Results:

• Boceprevir and telaprevir, approved in 2011, inhibit the NS3/4A protease and achieve up to 75% sustained virological response.
• Despite advancements, challenges with existing therapies persist, necessitating further research.
• Development is ongoing for inhibitors targeting NS5B, NS5A, and mutated NS3 protease.

Conclusions:

• New HCV protease inhibitors offer improved efficacy but still present challenges.
• Continued research into rational drug design is crucial for developing effective treatments against diverse and resistant HCV strains.
• Targeting viral enzymes like NS5B and NS5A represents a promising avenue for future HCV therapies.